immuno-oncology

News

Merck cuts $1bn deal with Janux for cancer T-cell therapies

In a deal that could top $1 billion, Merck & Co has teamed up with US biotech Janux Therapeutics to bring T-cell immunotherapies to cancer patients.

News

Catamaran joins the CAR-NK fleet, raising $42m in first roun...

Catamaran Bio has weighed anchor with a $42 million first-round financing that will be used to pull its off-the-shelf natural killer (NK) cell therapies for cancer through early-stage devel

Events

Partner Content

TGFB for Immuno-Oncology Drug Development Summit

Are you interested in finding the next breakthrough in immuno-oncology preclinical or clinical development?

News

Five Prime eyes financing after positive results with stomac...

Shares in US biotech Five Prime Therapeutics more than tripled after it reported promising trial results with stomach cancer drug candidate bemarituzumab, returning the stock to levels not

News

Genprex cancer gene therapy paired with AZ, Merck lung cance...

An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Co’s Keytruda - both leading their respective drug classes in the

News

FDA sets Feb decision date for Libtayo lung cancer challenge...

The FDA has started a priority review of Regeneron and Sanofi’s checkpoint inhibitor Libtayo in first-line non-small cell lung cancer (NSCLC), based on data they hope will carve out a niche

Merck cuts $1bn deal with Janux for cancer T-cell therapies

Catamaran joins the CAR-NK fleet, raising $42m in first roun...

TGFB for Immuno-Oncology Drug Development Summit

Five Prime eyes financing after positive results with stomac...

Genprex cancer gene therapy paired with AZ, Merck lung cance...

FDA sets Feb decision date for Libtayo lung cancer challenge...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

immuno-oncology

Editor's Picks